The specter of generic rivalry has long loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the prospects of connected drug ventures. While early periods saw significant profits, the exclusivity end has opened the door for less expensive copies, potentially lowering profitability and presenting a real risk for stakeho